

GLAXOSMITHKLINE PLC  
Form 6-K  
May 29, 2008

**FORM 6-K**

**SECURITIES AND EXCHANGE COMMISSION**  
**Washington D.C. 20549**

**Report of Foreign Issuer**

**Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934**

For period ending May 29, 2008

**GlaxoSmithKline plc**  
(Name of registrant)

**980 Great West Road, Brentford, Middlesex, TW8 9GS**  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

--

**FORM 8.3**

**DEALINGS BY PERSONS WITH INTERESTS IN SECURITIES REPRESENTING 1% OR MORE  
(Rule 8.3 of  
the  
Takeover  
Code)**

**1.  
KEY INFORMATION**

<b>Name of person dealing</b>	<b>GlaxoSmithKline plc and its subsidiaries</b>
(Note 1)	
<b>Company dealt in</b>	<b>CeNeS Pharmaceuticals plc</b>
<b>Class of relevant security to which the dealings being disclosed relate</b>	<b>Ordinary 30p shares</b>
(Note 2)	
<b>Date of dealing</b>	<b>2 9 May 2008</b>

**2.  
INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE**

(a)

**Interests  
and short positions**

**(following dealing) in the class of relevant security dealt in**  
(Note 3)

	<b>Long</b>	<b>Short</b>
	<b>Number</b>	<b>Number</b>
	<b>(%)</b>	<b>(%)</b>
<b>(1) Relevant securities</b>	<b>563,568</b>	
	<b>2.56%</b>	
<b>(2) Derivatives (other than options)</b>		
<b>(3) Options and agreements to purchase/sell</b>		
<b>Total</b>	<b>563,568</b>	
	<b>2.56%</b>	

(  
b  
)

**Interest  
positions  
and short positions**

**in relevant securities of the company, other than the  
class  
dealt in**

(Note 3)

<b>Class of relevant security:</b>	<b>Long</b>	<b>Short</b>
	<b>Number</b>	<b>Number</b>
	<b>(%)</b>	<b>(%)</b>
<b>(1) Relevant securities</b>		
<b>(2) Derivatives (other than options)</b>		

**(3)**  
**Options**  
**and agreements to purchase/sell**

**Total**

**(c)**  
**R**  
**ights to subscribe**

(Note 3)

**Class of relevant security Details**  
**:**

**3.**  
**DEALINGS**

(Note 4)

**(a)**

**Purchases and sales**

**Purchase/sale Number of securities Price per unit**

(Note 5)

**(b)**

**Derivatives transactions (other than options)**

**Pr Long/short Number of securities Price per unit**  
**oduct name (Note (Note 5)**

, 6 (Note 7)  
 )  
 e.g. CFD

(c)  
**O**  
 ptions transactions in respect of existing securities

(i)  
 Writing, selling, purchasing or varying

Product name , e.g. call option	Writing, selling, purchasing, varying etc.	Number of securities to which the option relates (Note 7)	Exercise price ,	Type , e.g. American, European etc.	Expiry d ate	Option money paid/received per unit (Note 5)
---	---	--	---------------------	--	--------------------	---

(ii)  
 Exercising

Product name , e.g. call option	Number of securities	Exercise price per unit (Note 5)
--	----------------------	--

(d)  
 Other dealings (including new securities)

(Note 4)

<b>Nature of transaction</b> (Note 8)	<b>Details</b>	<b>Price per unit (if applicable)</b>
<b>Issue of shares</b>	<b>120,752 Ordinary shares of 30p each issued pursuant to a share exchange agreement dated 21 November 2003 between CeNeS Pharmaceuticals plc and GlaxoSmithKline .</b>	(Note 5) <b>N ot Applicable</b>

**4.**

**O**

**OTHER INFORMATION**

**Agreements, arrangements or understandings relating to options or derivatives**

**Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.**

**Is a Supplemental Form 8 attached?**

(Note 9)

NO

<b>Date of disclosure</b>	<b>2 9 May 2008</b>
<b>Contact name</b>	<b>Victoria Whyte</b>
<b>Telephone number</b>	<b>020 8047 5000</b>
<b>If a connected EFM, name of offeree/offeror with which connected</b>	
<b>If a connected EFM, state nature of connection</b>	
<b>(Note 10)</b>	

*Notes*

*The Notes on Form 8.3 can be viewed on the Takeover Panel's website at [www.thetakeoverpanel.org.uk](http://www.thetakeoverpanel.org.uk)*

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

**GlaxoSmithKline plc**  
(Registrant)

Date: May 29, 2008

By: VICTORIA WHYTE  
-----  
Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc